{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RELAPSING+REMITTING+MULTIPLE+SCLEROSIS&page=2",
    "query": {
      "condition": "RELAPSING REMITTING MULTIPLE SCLEROSIS",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RELAPSING+REMITTING+MULTIPLE+SCLEROSIS&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T10:57:04.534Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01058005",
      "title": "Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00002 (natalizumab)",
          "type": "DRUG"
        },
        {
          "name": "interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "glatiramer acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2010-03",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-03",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 19,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01058005"
    },
    {
      "nct_id": "NCT02038049",
      "title": "A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapse Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "VAY736",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 8,
      "start_date": "2013-12-20",
      "completion_date": "2018-09-13",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 2,
      "location_summary": "Long Beach, California • San Diego, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038049"
    },
    {
      "nct_id": "NCT00050778",
      "title": "A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab 12 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alemtuzumab 24 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 334,
      "start_date": "2002-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 31,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050778"
    },
    {
      "nct_id": "NCT05482542",
      "title": "Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Autologous hematopoietic stem cell transplantation",
          "type": "OTHER"
        },
        {
          "name": "Cyclophosphamide/ATG",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide/Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Scripps Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-01-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05482542"
    },
    {
      "nct_id": "NCT00587691",
      "title": "Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "Tovaxin Autologous T Cell Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Opexa Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2002-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587691"
    },
    {
      "nct_id": "NCT05204459",
      "title": "MS-ResearchBiomarkerS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive",
        "Clinically Isolated Syndrome",
        "Radiologically Isolated Syndrome",
        "Neuromyelitis Optica Spectrum Disorders",
        "Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease",
        "Neurologic Autoimmune Disease",
        "Neurologic Disorder",
        "Healthy Aging"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2021-11-11",
      "completion_date": "2041-11-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-06",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05204459"
    },
    {
      "nct_id": "NCT01591551",
      "title": "NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Natalizumab (Tysabri)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cornerstone Health Care, PA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 37,
      "start_date": "2012-03",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-01-29",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 3,
      "location_summary": "Patchogue, New York • High Point, North Carolina • Portland, Oregon",
      "locations": [
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591551"
    },
    {
      "nct_id": "NCT01006265",
      "title": "Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "ACT-128800 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "ACT-128800 Dose 2",
          "type": "DRUG"
        },
        {
          "name": "ACT-128800 Dose 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 464,
      "start_date": "2009-10-01",
      "completion_date": "2011-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 25,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006265"
    },
    {
      "nct_id": "NCT04544436",
      "title": "A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 864,
      "start_date": "2020-11-26",
      "completion_date": "2028-08-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 24,
      "location_summary": "Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04544436"
    },
    {
      "nct_id": "NCT04009005",
      "title": "Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Clinically Isolated Syndrome",
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Therapeutic diet and lifestyle",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Terry L. Wahls",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2020-05-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-07-22T10:57:04.534Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04009005"
    }
  ]
}